Oncology

Molecular glues
#AstraZeneca #Francis Crick Institute #Molecular research #Oncology #University College London

Molecular glues could tackle ‘undruggable’ disease targets

UK researchers at the Francis Crick Institute, Imperial College London and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of different diseases, thanks to a £11.2 million combined investment. The investment includes a Prosperity Partnership grant from the Engineering and Physical… Read More

#Editor's Choice #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #The Institute of Cancer Research #University of Michigan

Uridine discovery could lead to new pancreatic cancer therapies

Pancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research has revealed. The findings suggest that blocking the availability of uridine using new drugs could become a new treatment strategy for the… Read More

#Cancer Research #News

Autophagy
#Cancer research #cellular #Japan #Liver cancer #Oncology #Proteomics

Study identifies protein complex with possible role in liver cancer

Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. Biomolecular condensates like p62 body have a role in cleansing cellular waste through ‘autophagy’, though much remains unknown about the constituents of… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR-T #Cell therapy #Gilead Sciences #Kite Pharma #National Institute for Health and Care Excellence (NICE) #Oncology

UK’s NICE expands use of CAR-T cell therapy for blood cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with… Read More

#News #Regulatory #Trending News

Peptide
#Bayer #Bicycle Therapeutics #Collaboration #Oncology #Partnership #Peptides #Radiochemistry

Bayer and Bicycle collaborate on bicyclic peptides

Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured and bind to targets with high affinity and selectivity,… Read More

#Cancer Research #News

Institute of Cancer Research
#Algok Bio #Cancer research #Oncology #Phase II trial #The Institute of Cancer Research

Ovarian cancer drug enters Phase II trials

An ovarian cancer drug, which targets the alpha folate receptor (FRα), is set to enter Phase II trials. Idetrexed (formerly known as BTG945, ONX-0901 and CT900) was created by scientific teams in what is now The Institute of Cancer Research (ICR) Centre for Cancer Drug Discovery,… Read More

#Cancer Research #News

#Drug development #Drug discovery #Immuno-oncology #Immunomodulators #Immunotherapy #Oncology

Podcast: Keep up to date with DDW Highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  DDW’s Diana Spencer has selected five stand-out news headlines this week, which all relate to immunotherapy… Read More

#News

Animal testing
#Animal models #Animal testing #Cancer research #Human disease models #Oncology #Preclinical development

Closing the translation gap in oncology drug development

Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for… Read More

#Cancer Research #Exclusive Content

#Drug development #Drug discovery #Immuno-oncology #Immunomodulators #Immunotherapy #Oncology

This week in drug discovery (1-5 May)

News round-up for 1-5 May by DDW Digital Content Editor Diana Spencer. My five stand-out news headlines this week all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances in our understanding of how other factors in the body, i.e., vitamin D levels and the… Read More

#News

Genetics
#Cancer research #Gene mutation #Genetics / genomics #Oncology #Precision medicine

3D genomics and targeted cancer therapies

Listen to this article on the DDW Podcast: Anthony Schmitt, PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. Efforts to fulfil the promise of precision medicine, including the use of targeted cancer therapies, necessitate that… Read More

#Cancer Research #Exclusive Content

T cell attacking cancer cell
#Cancer immunotherapy #Cancer research #Cell therapy #Immunotherapy #Oncology #Personalised medicine #Webinar

The future of cancer immunotherapy: exclusive webinar

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to… Read More

Webinar date:
Brought to you by BPS BioScience and AcroBiosystems
#News

The microbiome
#Cancer research #Gut microbiome #Harvard Medical School #Immunotherapy #Oncology #T cell activation

Gut microbes alter the body’s response to immunotherapy

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with… Read More

#Cancer Research #News #Trending News

Cancer cell
#Biotech #Cancer #iOnctura #Oncology #Pharmaceuticals

iOnctura expands pipeline and receives development grant 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline.   IOnctura also announced it has, in collaboration with the… Read More

#News

Cancer cell
#Cancer #Drug development #Oncology #Pharma

Scientific Affairs Group expands to over 200 oncologists  

Drug development company Ellipses Pharma now has more than 200 oncology experts from 106 institutions worldwide providing analysis and advice on selection of the most promising potential cancer medicines in its Scientific Affairs Group (SAG).   The number of experts joining the SAG has increased by 53% in… Read More

#News

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

Podcast: This week’s drug discovery highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Each of our top five stories this week exemplify the scientific curiosity that fuels the drug… Read More

#News

#Oncology #RNA #Solid tumours

New solid tumour panel could save time and expense 

Integrated DNA Technologies (IDT) has launched a new solution to optimise operational efficiency and the identification of solid cancer tumours.   The IDT Archer FUSIONPlex Core Solid Tumor Panel is a first-line cancer research testing solution that has been expanded and optimised for additional single nucleotide variant (SNV)… Read More

#News